NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
Imaging studies of more than 27,000 adults link a healthier thymus on CT scans with a longer life and lower risks of ...
This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the Centers for Disease Control. But the field of cancer vaccines, which can be ...
Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...
Adoptive cell therapy (ACT) has emerged as a transformative approach in cancer immunotherapy, with remarkable clinical success in hematological ...
With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...
In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results